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Smooth muscleChronic kidney disease (CKD) is associated with vascular calciﬁcations and atherosclerosis. There is a need for
novel predictors to allow earlier diagnosis of these disorders, predict disease progression, and improve
assessment of treatment response. We focused on microRNAs since they are implicated in a variety of cellular
functions in cardiovascular pathology. We examined changes of microRNA expression in aortas of CKD and
non-CKD wild type mice and apolipoprotein E knock-out mice, respectively. Both vascular smooth muscle-
speciﬁc miR-143 and miR-145 expressions were decreased in states of atherosclerosis and/or CKD or both, and
the expression level of protein target Myocardin was increased. The inﬂammatory miR-223 was increased in
more advanced stages of CKD, and speciﬁc protein targets NFI-A and GLUT-4 were dramatically decreased.
Expression ofmiR-126wasmarkedly increased and expression of protein targets VCAM-1 and SDF-1was altered
during the course of CKD. The drug sevelamer, commonly used in CKD, corrected partially these changes in
microRNA expression, suggesting a direct link between the observed microRNA alterations and uremic vascular
toxicity. Finally, miR-126, -143 and -223 expression levels were deregulated in murine serum during the course
of experimental CKD. In conclusion, these miRNAs could have role(s) in CKD vascular remodeling and may
therefore represent useful targets to prevent or treat complications of CKD.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Patients with late stages of chronic kidney disease (CKD) exhibit a
dramatic increase in cardiovascular morbidity and mortality [1] which
is associated with an early appearance of vascular and valvular
calciﬁcations and atherosclerosis. Vascular calciﬁcation is attributed, at
least in part, to an active mechanism resembling bone formation [2]. It
is widely considered that identiﬁcation of nontraditional predictors
underlying this complex mineralization process will be increasingly-Out; Chol, Cholesterol; CKD,
e 4; miRNA, microRNA; MYO,
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etzinger).
ights reserved.useful for the diagnosis of CKD-related vascular disease. MicroRNAs
(miRNAs) are small molecules that comprise a groundbreaking class
of endogenous interfering RNAs [3]. A wealth of recent work has
shown that, since miRNAs are instrumental players in the ﬁne-tuning
of gene regulation, they have signiﬁcant value as biomarkers of
cardiovascular disease etiology and progression [4,5]. Limited literature
data suggest that miRNAs are involved in the development of vascular
damage in CKD [6]. Several among them have been shown to be
important regulators of vascular smooth muscle cell (VSMC) growth
and proliferation of endothelial cell plasticity and damage [7–9].
To our knowledge, miRNA expression in large vessels during the
course of experimental CKD and CKD-associated atherosclerosis has
not been studied so far. We therefore decided to analyze the expression
of six cardiovascular-related miRNAs [9] in aortas from murine models
with CKD, atherosclerosis, and vascular calciﬁcation [10]. Wild type
(WT) C57BL/6J as well as Apolipoprotein-E knock-out (Apo-E KO)
mice underwent partial nephrectomy to induce CKD. Apo-E KO mice
characteristically develop large atheromatous plaques and low-grade
vascular calciﬁcation. The combination of ApoE-KO and CKD leads to
more marked atherosclerosis and aortic calciﬁcation than in Apo-E KO
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develop atherosclerosis [10].
The pro-angiogenic miR-126 is abundant in endothelial cells [11]
plays an important role in vascular dysfunction and modulates the
expression of Vascular Cell Adhesion Molecule-1 (VCAM-1) [12] and
of chemokine Stromal cell-Derived Factor-1 (SDF-1/CXCL-12) [13].
miR-143 and miR-145 are highly expressed and speciﬁc for VSMCs
and have instrumental roles in vascular biology and pathology
(reviewed in ref. [7]). Elia et al. [14] reported that the expression levels
of miR-143 and miR-145 were decreased in conditions of acute and
chronic vascular damage. Boettger and colleagues [15] observed that
co-expression of the mouse miR-143/145 cluster was required for
VSMC acquisition of the contractile phenotype. Importantly, Cordes
et al. [16] demonstrated that miR-145 directed the smooth muscle
fate, and miR-145 and miR-143 combined function to regulate the
quiescent vs. proliferative phenotype of smooth muscle cells, by
regulating the VSMC-speciﬁc transcription factor myocardin (MYO).
Of note, our group showed that the uremic toxin inorganic phosphate
(Pi; elevated in CKD) decreased miR-143 and miR-145 expression
in vivo and in vitro [17]. The anti-angiogenic homolog miRNAs miR-
221 and miR-222 are highly expressed by both vascular endothelial
cell and VSMC, where they have been shown to regulate survival,
proliferation and differentiation [18–20]. Finally, we have studied the
expression of the inﬂammatory miRNA miR-223 [21]. An increase of
miR-223 was reported in damaged skeletal muscle areas from
Duchenne muscular dystrophy [22], in cardiomyocytes [23] and in
VSMC [17]. Interestingly, miR-223 is linked with osteogenesis and
calcium-phosphate deposits [24].
In the present study, we have obtained evidence suggesting that
CKD-associated vascular damage leads to aorta down-regulation of
miR-143 and miR-145 expression, up-regulation of miR-126 and miR-
223 expression, and marginal changes of miR-221 and miR-222
expression, with concomitant changes in murine serum. These
alterations were correlated with changes in the expression of
their most important target genes. Treatment with sevelamer, a
phosphate binder and modulator of other uremic toxins that also
displays anti-oxidant and anti-inﬂammatory effects, partially
reversed the changes in miRNA expression induced by this
pathologic state. Altogether, our ﬁndings strongly suggest an
implication of miRNAs in the vascular remodeling of mice with
CKD and atherosclerosis.2. Materials and methods
2.1. Animal and cell culture procedures
All experiments were performed in female mice (Charles Rivers), as
they develop vascular calciﬁcations more rapidly than their male
counterparts [1]. Animals were housed in polycarbonate cages in
temperature- and humidity-controlled rooms with a 12:12-hour light-
dark cycle and were given standard chow (Harlan Teklad Global Diet
2016) and tapwater ad libitum. The studywas performed in two different
mousemodels: wild type C57BL/6J (WT)mice and Apo-E KOmice, which
share the same genetic background. All animal studieswere conformed to
the principles of the Directive 2010/63/EU of the European Parliament
and all protocols were approved by our Institution's Animal Care and
Use Committee (CREMEAP). Mice were anesthetized with ketamine and
xylazine (80mg/kg and 8mg/kg), and all efforts were made to minimize
suffering. We used a previously described two-step procedure to create
CKD [10]. Brieﬂy, we applied cortical electrocautery to right kidney
and then performed left total nephrectomy 2 weeks later. Control
animals underwent SHAM operations. Sevelamer-carbonate or
placebo was administered as a 3% mix with animal chow. Sevelamer
treatment was started 2 weeks after CKD induction and continued
for 8weeks.Human endothelial cells from umbilical vein HUV-EC-C, No CRL-
1730 were purchased from ATCC and grown according to the supplier's
instructions. Anti-miR transfections were performed as described in ref.
[17].2.2. Serum biochemistry
Cardiac blood was chilled and spun at 7000g for 15 min in a
refrigerated centrifuge. Serum was then stored at −80 °C until further
use. Urea, total Chol, calcium, Pi and TG were assessed using an ADVIA
1800 Siemens Autoanalyzer (Siemens).2.3. Western blotting analysis
Aortas were ground using Bio-Gen PRO200 laboratory tissue
homogenizer (PRO Scientiﬁc Inc.) in 50mMTris, 150mMNaCl, 1% triton,
0.1% SDS, 1mM PMSF. The homogenates were sonicated for 10seconds
per aorta. After centrifugation at 12,000g at 4°C for 20min, supernatants
containing the aorta lysates were collected. Equal amounts of protein
(15–30 μg) were resolved by SDS-PAGE on 10% polyacrylamide gels.
Then, the proteins were transferred to a Hybond-C extra membrane
(Amersham Bioscience), the membrane was blocked for 1 h with 5%
non-fat dry milk in Tris-buffered saline (1×) containing 0.01% Tween
20 (TBST). The membrane was then incubated with primary antibodies
at the following concentrations: mouse anti-MYO and mouse anti-
VCAM-1 at 1:1000, rabbit anti-SDF-1, rabbit anti-NFIA and rabbit
anti-GLUT-4 at 1:500. Horseradish peroxydase (HRP)-linked goat
anti mouse antibody was used at 1:5000, HRP-linked goat anti
rabbit antibody was used at 1:2500. After washing with TBST, the
membranes were revealed using enhanced chemiluminescent
reagent, ECL plus (GE Healthcare) for 3 min. Primary antibodies
anti-MYO, -VCAM-1, -SDF-1, -NFI-A and -GLUT-4 were purchased
from Abcam. All secondary antibodies were purchased from Santa
Cruz biotechnology.2.4. RNA isolation and real-time PCR
RNA isolation and RT-qPCR were performed as described previously
[17]. Brieﬂy, RNA from whole aorta, cell culture or mouse sera (200–
300 μL) was isolated using themirVana™miRNA Isolation Kit (Applied
Biosystems), according to the manufacturer's instructions. RNA was
further subjected to DNAse-I digestion. Syn-cel-miR-39 miScript
miRNA Mimic (Qiagen) was spiked in the RNA samples and used
as an exogenous control for data analysis of murine sera, as
described in ref. [25]. For all miRNAs, Taqman assays available
from Applied Biosystems were used for cDNA synthesis and real-
time PCR. U6 (miRNAs from aorta or cell culture) and Syn-cel-miR-
39 Mimic (miRNAs from serum) were used as endogenous controls.
Real-time PCR was performed on a StepOne Plus setup (Applied
Biosystems).2.5. Statistical analysis
Data from T2, T4 and T10 mice were analyzed by ANOVA two-
way test (*CKD vs. SHAM, and † or §WT vs. Apo-E KO) and data
from T0 mice and Sevelamer treatment mice were analyzed by
Student t-test. Data from murine sera were analyzed by Mann–
Whitney test. Results were expressed as mean ± SEM. Spearman
tests were performed to detect correlations between biochemical
parameters and miRNA expression. Differences between groups
were considered signiﬁcant at * (or †) P b 0.05, **(or ††) P b 0.01,
*** (or †††) P b 0.001.
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CKD is associated with enhanced atherosclerosis and increased
aortic stiffness by as yet poorly understood mechanisms [1]. In order
to identify additional clues, we have examined changes of vascular
miRNA expression in a murine model of CKD with atherosclerosis and
vascular calciﬁcation (i.e. Apo-E KO mouse), as opposed to another
murine model without atherosclerosis and calciﬁcation (i.e. WT
mouse), and compared results to known biochemical parameters. To
characterize baseline conditions, a group of mice were sacriﬁced at
8weeks of age (T0)without any surgical intervention. The other animal
groups were sacriﬁced 2weeks (T2), 4weeks (T4), and 10weeks (T10)
after subtotal nephrectomy, respectively.
3.1. Serum biochemistry, aortic calciﬁcations and atherosclerosis in
association with CKD
As expected, serum urea levels were increased in mice with CKD,
both WT and ApoE-KO, as compared to SHAM mice, 2 weeks after
subtotal nephrectomy (T2). Serum total calcium levels were also
signiﬁcantly increased in same CKD mice compared with SHAM mice.
In contrast, there was no change in serum phosphate levels. Apo-E KO
mice had a signiﬁcant increase of serum total cholesterol (Chol) and
triglyceride levels throughout the experiment, compared with WT
mice (Supplementary Table I). CKD led to a further increase in serum
total Chol in Apo-E KO.
Fourweeks after subtotal nephrectomy (T4),we still observed a CKD
effect on calcium levels which were increased 1.2 times in all CKDmice
(Supplementary Table I). Urea levels were still increased in CKDmice by
almost 5 times vs. SHAM. In regard to Chol and TG levels, we
ascertained both an Apo-E KO effect and a CKD effect: indeed
Chol level were increased in Apo-E KO mice vs. WT mice by
approximately 4 times, and in CKD mice vs. SHAM mice, by almost
1.5 times. We detected a doubling of TG levels in Apo-E KO CKD
mice vs. WT CKD, and a decreased level in WT CKD mice vs. WT
SHAM mice 1.7 times.
At 10 weeks after subtotal nephrectomy (T10), CKD still induces
calcemia with an increase by approximately 1.2 times in CKD mice
(WT and Apo-E KO). Concerning Pi levels, we observed a strong Apo-E
KO effect with a signiﬁcant diminishment in Apo-E KO SHAM vs. WT
SHAM. As expected, urea levels were still enhanced by four times in
operated mice. Chol level was increased in Apo-E KO mice by
approximately 5 times vs. WT mice, as were TG levels. A CKD effect on
Chol was detected (Supplementary Table I).
Valvular calciﬁcations were evaluated by von Kossa staining in
cryosections of aortic tissue which allows distinction of intimal
and medial calciﬁcations (representative pictures are shown in
Supplementary Fig. 1). In aortic root cryosections there was a
signiﬁcant increase at T10 of percent calciﬁed area in Apo-E KO
mice compared with WT mice (P b 0.015) and in CKD Apo-E KO
mice compared with Apo-E KO SHAM mice (P b 0.05). These
data conﬁrm previous personal results with same animal models
[10,26].
3.2. Dowregulation of miR-143/miR-145 expression in aortas of Apo-E KO
mice in absence or presence of CKD and modulation of MYO expression
At ﬁrst, we veriﬁed that the expression of our endogenous control,
the RNA spliceosome gene U6, was not signiﬁcantly changed between
WT SHAM mice and the various pathological conditions (data not
shown). At baseline, there was no detectable effect of Apo-E KO state
on either miR-143 or miR-145 expression. Subsequently, we observed
a signiﬁcant decrease of miR-143 in both Apo-E KO SHAM and Apo-E
KO CKD mouse aortas, by respectively 1.3 and 1.8 times vs. WT mice
at T2, 2.7 and 1.7 times vs. WT mice at T4, and 1.5 and 1.2 times vs.
WT mice at T10 (Fig. 1A). Similar results were found for aorticmiR-145 expression (Fig. 1B). The decline ranged respectively from
1.4 and 1.7 times vs. WT mice at T2, to 1.7 and 1.3 times vs. WT mice
at T10. At T10 there was also a reduction in miR-145 levels in WT CKD
and Apo-E KO CKD mice, 1.5 and 1.1 times, respectively, vs. SHAM. As
to the expression of transcription factor MYO, which is regulated by
both miR-143 and miR-145 [7], there was no difference at T0 or T2
(Fig. 1C). However, a marked effect became apparent after 10weeks of
CKD when MYO levels were increased in both WT and Apo-E KO mice
with CKD, 1.7 and 1.2 times respectively vs. SHAM mice. There also
was an Apo-E KO effect since MYO expression was decreased in Apo-E
KO CKD mice vs. WT CKD mice. RT-qPCR experiments were also
performed to quantify the expression of two targets of the miR-
143-145 cluster involved in migration and proliferation, versican
and PDGFRα, in aortas from mice corresponding to the three
pathological conditions. Our results indicate that versican mRNA
expression was increased at T10 in CKD mice vs. SHAM control
mice, as expected in view of the decrease in miR-143 and miR-145
in pathological mice (Supplementary Fig. 2). A trend towards an
increase of PDGFRα expression was also observed at T10 in Apo-E
KO CKD mice, but was not statistically signiﬁcant (Supplementary
Fig. 2).
3.3. Modulation of NFI-A and GLUT-4 expression by miR-223 in Apo-E KO
aortas in absence or presence of CKD
At baseline, no signiﬁcant difference in miR-223 expression was
detected between Apo-E KO and WT mice (Fig. 2A). In contrast, at T2
a signiﬁcant increase was detected in both CKD groups (1.2 and 1.8
times respectively). At T4, miR-223 expression was increased in Apo-E
KO SHAM and Apo-E KO CKD mice 1.1 and 1.8 times respectively. We
detected a signiﬁcant Apo-E KO effect on miR-223 expression
(Fig. 2A). Finally, at T10 we found an increase in miR-223 expression
of 1.6 and 1.5 times in CKD mice compared to SHAM, and in Apo-E KO
mice 1.4 and 2.2 times respectively vs. WT mice (Fig. 2A). It was
reported that miR-223 targets the transcription factor Nuclear Factor
I/A (NFI-A) in osteoclasts [24] and VSMCs [17], and the glucose
membrane transporter glucose transporter type-4 (GLUT-4) in
cardiomyocytes [23]. At baseline, NFI-A expression was diminished in
Apo-E KO SHAMmice 1.8 times vs. WT SHAM. At T10, NFI-A expression
was lessened in CKD mice (WT and ApoE-KO) vs. SHAMmice, and in
Apo-E KO mice (SHAM and CKD) 1.7 and 1.2 times respectively vs.
WT mice. This decrease is concomitant with the increase of miR-
223 (Fig. 2B). Comparable results were obtained when looking at
GLUT-4, another target of miR-223. We did not detect any difference
of expression of GLUT-4 at T2 or T4, but we observed a strong
decrease at T10 in CKD mice vs. SHAM, of 1.4 and 2.3 times
respectively. In Apo-E KO mice, the decline was of 1.6 and 2.8
times respectively vs. WT mice (Fig. 2B). In conclusion, we found
at T10 a signiﬁcant decrease of two miR-223 targets in CKD and
Apo-E KO aortas which parallels the increase of miR-223 in these
mice at the same stage of illness.
3.4. miR-126 expression is increased in CKD and Apo-E KO mice aorta
No signiﬁcant difference was observed concerning miR-126
expression in aortas at T0. In contrast, at T2, miR-126 expression was
signiﬁcantly enhanced in CKD mice aortas (WT and Apo-E KO) 1.2 and
2.2 times respectively vs. SHAM mice; at T4, miR-126 increased
signiﬁcantly in Apo-E KO SHAM and Apo-E KO CKD mice aortas 1.3
and 2.9 times respectively vs. WT mice (Fig. 3A). Also, miR-126 is
increased in all aortas of mice afﬂicted at T10 with a signiﬁcant CKD
effect. Indeed miR-126 expression is enhanced in CKD mice 2 and 1.1
times respectively versus SHAM counterparts. Surprisingly, VCAM-1
and SDF-1, which are well established targets of miR-126 [12,13] are
enhanced in pathological conditions (Fig. 3B). At T10,we found an effect
of Apo-E KO on VCAM-1 expression, with an enhancement in Apo-E KO
Fig. 1. Expression ofmiR-143,miR-145 and targetMYO inCKDmicewithout orwith atherosclerosis.Mice aortaswere isolated fromWild type andApoE-KOmice formiRNAandprotein studies
at indicated times. (A) MiR-143 andmiR-145 expression expressed as RQ normalized to U6. (B) MYO expression normalized to ß-actin as determined byWestern blotting (n=4±S.E.M. for
miRNA, n=4±SEM forMyocardin,*Pb 0.05 CKDmice vs. Sham, † Pb0,05 Apo-E KOmice vs.WT). For T0 data statistical signiﬁcancewas determined by Student's t test (n=4,means± SEM,
Δ P b 0.05).
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Fig. 2. Expression ofmiR-223 and its targets GLUT-4 and NFIA in CKD and atheroscleroticmice.Mice aortaswere isolated fromWild type and ApoE-KOmice formiRNA and protein studies
at indicated times. (A) miR-223 expression expressed as RQ normalized to U6. (B) NFIA and GLUT-4 expression respectively normalized with ß-actin. Statistical signiﬁcance was
determined by a two-way ANOVA (n=4, means± SEM for miRNA, n=5, means± SEM for NFIA and n=4, means± SEM for GLUT-4, *P b 0.05 CKD mice vs. Sham mice, † P b 0.05
Apo-E KO mice vs.WTmice). For T0 data statistical signiﬁcance was determined by Student's t test (n=4, means± SEM, Δ P b 0.05 Apo-E KO Sham vs.WT Shammice).
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Fig. 3. Expression of miR-126 and its targets SDF-1 and VCAM-1 in CKD and atherosclerotic mice. Mice aortas were isolated from Wild type and ApoE-KO mice for miRNA and protein
studies at indicated times. (A) miR-126 expression expressed as RQ normalized to U6. (B) VCAM-1 and SDF-1 expression normalized to ß-actin (n=4, means±SEM for miRNA studies,
n=4 means± SEM for SDF-1 studies and n=3, means± SEM for VCAM-1 studies, *P b 0.05 CKD mice vs. Sham mice, † P b 0.05 Apo-E KO mice vs. WT mice.). For T0 data statistical
signiﬁcance was determined by Student's t test (n=4, means± SEM, Δ P b 0.05).
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SHAM. We next looked at another mir-126-speciﬁc target SDF-1. We
did not detect any signiﬁcant difference of expression at T0, but at T2,
we observed an increase in the expression of SDF-1 in WT CKD and
Apo-E KO CKD mice, 1.6 and 1.3 times respectively vs. SHAM (Fig. 3B).
At T10, SDF-1 was increased inWT CKD and Apo-E KO CKDmice aortas
4.1 and 2.2 times respectively vs. SHAM (Fig. 3B). In order to determine
whether this regulation was also observed in vitro, miR-126 inhibitors
were injected into HUV-EC-Cs endothelial cells that mainly express
miR-126. Our results show that, in vitro, mir-126 antisense treatment
strongly enhanced the expression of the miR-126-speciﬁc targets,
VCAM and CXCL12/SDF1 (Supplementary Fig. 3), as expected from the
mechanism of action classically described for miRNA.
3.5. Mild changes in aortic miR-221 and miR-222 expression in association
with Apo-E KO and CKD status
Signiﬁcant variations of miR-221/222 expression were not detected
in pathological conditions, from the induction of uremia to the end of
the experiment except at T4. In these conditions, at T4, miR-221 was
decreased in Apo-E KO mice (SHAM and CKD) 2.3 and 1.4 times
respectively and miR-222 expression was diminished 1.9 and 1.2
times respectively vs. WT (Supplementary Fig. 4). Given these mixed
results, we decided not to further explore miR-221 and miR-222
implications in our models.
3.6. Correlation between aortic miRNA expression and serum biochemistry
parameters
We tested Spearman correlation coefﬁcients between blood
parameters and the expression of miRNAs in aortas (Table 1). In the
total population, we found a signiﬁcant correlation between the
expression of all miRNAs studied and Chol levels, starting as early as
T2 for miR-145 and at T4 for the rest of miRNAs, and continuing
throughout the experiment. We also detected at T10 a strong
correlation betweenmiR-223 and the serum levels of both total calciumTable 1
Correlation between miRNA expression in aorta and biochemical parameters.
Calcium Phosphorus Urea
Total population
miR-126 p
rho
* / – / –
0.613 / – / –
0.06 / – / –
0.502 / – / –
– / – / –
– / – / –
miR-143 p
rho
– / – / –
- / - / –
– / – / 0.06
– / – / 0.436
– / – / –
– / – / –
miR-145 p
rho
– / – / –
– / – / –
– / – / 0.09
– / – / 0.372
– / – / –
– / – / –
miR-223 p
rho
– / – / *
– / – / 0.494
0.06 / – / –
0.424 / – / –
– / – / *
– / – / 0
Apo-E KO population
miR-126 p
rho
* / – / –
0.795 / – / –
– / – / –
0.502 / – / –
* / – / –
0.838 /
miR-143 p
rho
– / * / –
– / 0.810 / –
– / * / –
– / 0.755 / –
– / * / –
– / 0.90
miR-145 p
rho
– / – / –
– / – / –
– / – / –
– / – / –
* / ** / –
−0.629
miR-223 p
rho
– / – / *
– / – / 0.764
– / – / –
0.424 / - / -
– / * / *
– / 0.83
WT population
miR-126 p
rho
– / * / 0.07
– /−0.755 / 0.508
0.08 / – / –
0.667 / – / –
– / – / –
– / – / –
miR-143 p
rho
– / – / –
– / – / –
– / – / –
– / – / –
– / – / *
– / – /−
miR-145 p
rho
– / – / 0.08
– / – /−0.503
– / – / –
– / – / –
– / – / 0
– / – /−
miR-223 p
rho
– / – / *
– / – / 0.697
– / 0.09 / –
– / 0.643 / –
– / – / *
– / – / 0
Correlation tests between biochemical results and miRNA expression levels. Spearman correl
⁎⁎⁎p b 0.001.and urea. miR-145 was correlated with TG levels at T4 but not at T10,
although such a correlation was not found for miR-143. miR-126 was
correlated with calcium level at T2. Finally, miR-143/145 levels were
close to signiﬁcance regarding serum phosphorus level at T10. When
looking at WT or Apo-E KO mice separately, most of the correlations
still exist. Chol correlation however appears only at T2 concerning
miR-126, at T4 for miR-143 and at T10 for miR-223. A correlation
between miR-223 and TG appears at T10 with WT and throughout
experiment with Apo-E KO. This was not apparent in the total
population. MiR-143 is correlated at T4 with calcium, phosphorus, and
urea in the Apo-E KO population, and urea and TG at T10 in the WT
population.
3.7. Partial reversal of altered miRNA expression by sevelamer
In order to assess a causality link between the miRNAs we studied
and aorta pathology, we treated SHAM and CKD WT mice with the
phosphate binding drug sevelamer. We measured levels of miR-126,
miR-143 and miR-223 in order to respectively assess the endothelial
dysfunction, the smooth muscle cell biology, and the inﬂammatory
state. Sevelamer or placebo was administered mixed with animal
chow, at a proportion of 3%. Sevelamer treatment was started 2weeks
after CKD induction and continued for 8weeks (Fig. 4A). Blood samples
were collected 1 week before starting the treatment and again at
sacriﬁce. As expected, an 8-week treatment by sevelamer decreased
serum phosphate by 25% in CKD mice (2.5 ± 0.7 mmol/l in sevelamer
CKD group vs. 3.1±0.7 in placebo CKD group). In contrast, sevelamer
did not alter serum phosphate in SHAM mice (2.4 ± 0.4 7 mmol/l in
active treatment group vs. 2.3± 0.3 in placebo group). As observed in
the preceding experiment (Fig. 3), miR-126 was increased 2 times in
control CKD as compared to control SHAM. The same was true when
comparing sevelamer-treated CKD mice to sevelamer-treated SHAM
(Fig. 4B). Interestingly, miR-126 levels were decreased 1.6 times in
sevelamer CKD and sevelamer SHAM groups vs. control SHAM and
control CKD groups. ConcerningmiR-143, therewas a 1.4 times increase
of miR-143 expression in sevelamer-treated SHAM mice vs. controlTriglycerides Cholesterol
– / – / –
– / – / –
– / * / *
– / 0.609 / 0.419
– / – / –
– / – / –
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– / – / –
– / – / –
– / ** / ***
– / 0.682 / 0.724
– / –
– / – / –
– / – / –
* / – / –
0.766 / – / –
5 / –
– / – / –
– / – / –
– / 0.07 / –
– / 0.690 / –
/ 0.976 / -
– / 0.06 / –
– /−0.714 / –
– / – / –
– / – / –
3 / 0.715
0.09 / * / 0.06
−0.542 /−0.738 /−0.591
– / – / 0.06
– / – / 0.582
– / – / –
– / – / –
– / – / –
– / – / –
0.613
– / – / *
– / – / 0.715
– / – / –
– / – / –
.07
0.520
– / – / –
– / – / –
– / – / –
– / – / –
.635
– / – / *
– / – /−0.696
– / – / *
– / – / 0.665
ation test, p at week 2 / week 4 / week 10 of CKD respectively. ⁎p b 0.05, ⁎⁎p b 0.01 and
Fig. 4.miR-126, miR-143 andmiR-223 expression in control and sevelamer-treatedWild-Type (WT)mice aortas. (A) Experimental design. After induction of CKD by electrocauterization
(EC) of right kidney and two weeks later by total nephrectomy of left kidney (NX), WTmice were treated, or not (control), with 3% sevelamer-CO3mixed in chow during 8weeks, from
2weeks to 10weeks after nephrectomy. At the age of 8weeks,micewere randomly associated to four groups: SHAMmicewith control treatment, CKDwith control treatment, SHAMmice
with sevelamer treatment, CKDmice with sevelamer treatment. Aortaswere collected for miRNA studies 10weeks after nephrectomy. (B)miRNA expression expressed as RQ normalized
to U6 (n=6–10, means±SEM, statistical signiﬁcancewas determined by Student's t test, *Pb0.05, **Pb0.01 ***Pb0.001 CKD vs. SHAMmice, §Pb0.05, §§Pb0.01, §§§Pb0.001 Sevelamer
vs. control mice).
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expression 1.5 times in actively treated CKD vs. placebo-treated CKD
mice (Fig. 4B). As expected, miR-223 expression was increased in CKD
groups 3.7 and 3.3 times in control and sevelamer-treated mice
respectively. Here again, sevelamer treatment reduced this increase in
treated mice both SHAM and CKD mice 1.8 and 1.6 times respectively
as compared to placebo-treated mice (Fig. 4B).3.8. Alteration of miRNA expression in the serum of pathological mice
To assess miR-126, miR-143, miR-145 and miR-223 as putative
noninvasive biomarkers in our murine models, their expression was
analyzed in the serum of uremic (CKD) and Apo-E KO mice 2 weeks
and 10 weeks post-nephrectomy. An exogenous control, Syn-cel-miR-
39, was spiked in the RNA samples and used as an exogenous control
for data analysis of murine sera, as previously described in ref. [25].
At T2, corresponding to the earliest stage of uremia, miR-126, miR-
143 and miR-223 expressions were signiﬁcantly decreased in sera
from Apo-E KO SHAM mice versus WT SHAM mice (Fig. 5A). More
precisely, miR-126 was decreased 2.5-fold in Apo-E KO SHAM mice
versus WT SHAM mice, miR-143 was decreased 4.2-fold, and miR-223
was decreased 2.3-fold times in Apo-E KO SHAM mice versus WT
SHAM mice. A trend towards an increase of miR-145 expression was
observed in WT CKD mice versus SHAM counterparts, but was not
statistically signiﬁcant.
At T10, expression of the inﬂammatorymiR-223 and the endothelial-
speciﬁc miR-126 was strongly and signiﬁcantly decreased in WT CKD
mice versusWT SHAMmice (Fig. 5B; 2.7-fold and 5.6-fold, respectively),
whereas the expression of the same miRNAs was increased in Apo-E KO
CKD mice versus WT CKD mice (2.6-fold for both). The VSMC-speciﬁc
miR-143 was decreased in both WT CKD and Apo-E KO SHAM mice
(3.8-fold and 2.3-fold, respectively versus WT SHAM). No signiﬁcantdifference in miR-145 expression was observed at this stage of uremia
(Fig. 5B).4. Discussion
The purpose of our study was to assess the expression of
cardiovascular-related miRNAs during the course of rapidly progressive
atherosclerosis and vascular calciﬁcation in association with the
progression of CKD [27,28]. We demonstrate here the detection of miR-
126, miR-143, miR-145, miR-221, miR-222 and miR-223 expression in
aortic tissue of normal (WT) mice, WT mice with CKD, and Apo-E KO
mice with superimposed CKD. Importantly, their expression levels, and
those of their speciﬁc protein targets, are altered by CKD status.
The biochemical data described in our paper conﬁrm previous
reports already published by our laboratory [1,10]. We expectedly
show that urea is increased in mice with CKD and that cholesterolemia
is present in Apo-E KO mice, and aggravated in the presence of CKD
[1,10,29]. Moreover, CKD and atherosclerotic models display a strong
accumulation of calcium-phosphate deposits. We demonstrate here
that miRNAs levels are correlated with classical biomarkers of CKD
and atherosclerosis such as Chol and TG, which reﬂect atherosclerosis,
and urea levels, which reﬂect the renal function. Throughout the
experiment, and especially at the later stages of CKD, we found that
both miR-143 and miR-145 levels were decreased in the two
pathological disease states. The data we present here are in agreement
with related models reported by our group and others. Indeed, Elia
et al. [14] already found that miR-143 and -145 are lowered in acute
and chronic vascular damage. In VSMC in vitro, we detected a similar
decrease [17]. The silencing of the miR-143/145 cluster was
demonstrated to direct VSMC from a quiescent to a proliferative, i.e.
pathologic, phenotype. This process was dependent of one of their
targets, the VSMC-speciﬁc transcription factor MYO [15,16]. Here, we
Fig. 5. miR-126, miR-143, miR-145 and miR-223 expression in sera from Apo-E KO and CKD mice. Murine sera were isolated from wild-type and Apo-E-KO mice for miRNA studies
at indicated times. (A) miRNA expression was expressed as RQ normalized to cel-miR-39 at two weeks after nephrectomy. (B) miRNA expression was expressed as RQ normalized to
cel-miR-39 at ten weeks after nephrectomy. Statistical signiﬁcance was determined by Mann–Whitney test (n= 6–12 ± S.E.M., *P b 0.05, **P b 0.01, ***P b 0.001 CKD mice vs. Sham
mice; †P b 0.05, ††P b 0.01, †††P b 0.001 Apo-E KO mice vs.WT mice).
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both CKD and atherosclerosis induces a similar decrease in these
miRNAs. We show that the expression of MYO increases concomitantly
with the downregulation of miR-145 in ApoE-KO when compared with
WT, and thus agree with Cordes et al., who have demonstrated that
miR-145 increases the expression of MYO [16]. On the other hand, we
also noticed an increase of MYO concomitant with a decrease of miR-
145 in operated mice, when compared with SHAM, indicating that the
regulation of MYO by miR-145 is complex. MYO is a VSMC-speciﬁc
transcription factor which both regulate miR-143/145 and is regulated
by them [7]. miR-143/145 cooperatively targets a network of
transcriptions factors including MYO to promote differentiation and
repress proliferation of VSMCs [7,16]. MYO also helps to maintain the
VSMC phenotype [7]. The increase in MYO observed in response to a
decrease in miR-143 and miR-145 is therefore likely to maintain the
phenotypic balance towards a differentiated state in response to various
pathophysiological stresses. Based on these ﬁndings, we hypothesize
that the decrease in miR143/145 in mice with CKD and atherosclerosis
participates in the induction of VSMC transdifferentiation, despite the
concomitant increase in MYO.
One of our study's most important ﬁndings was the up-regulation of
miR-223 in aortas of CKD mice and also in SHAM operated Apo-E KO
mice. miR-223 is widely considered as a tumor-speciﬁc miRNA (e.g.
[30]). However, recent literature shows that it is also amarker of cardiac
[23], skeletal [22] or smooth [17] muscle damage. We recently reported
that miR-223 is expressed in VSMCs and is upregulated in the presence
of the uremic toxin Pi, which in turn induces a switch towards the
proliferative phenotype [17]. We found similar results in mouse aortas.
We thus speculate that miR-223 is linked with the VSMC complex
response to CKD. We cannot formally exclude a participation of
endothelial cells, but miR-223 expression was not detected in this cell
type [11]. Chronic low-grade inﬂammation plays a key role in the
initiation of angiogenesis in chronic inﬂammatory diseases [31]. The
strong increase in miR-223 expression we found ﬁts well with this
miRNA's involvement in inﬂammatory processes [21]. The decrease
observed at the later stages of CKD in miR-223 targets, NFIA, a
transcription factor downregulated during uremic toxin exposure [17],
and GLUT-4 could participate to VSMC metabolic damage. miR-223
could participate in the insulin resistance, an independent risk factor
in CKD [32], by modulating expression levels of GLUT-4 [23,33].
miR-126 is prevalent in endothelial cells, where it enhances blood
vessel formation [8]. Plasma levels of miR-126 have been shown to be
decreased in type 2 diabetes [34]. We are to our knowledge the ﬁrst to
show that miR-126 is overexpressed in mouse aortas throughout CKD
with a concomitant deregulation of its targets. Harris et al. have
demonstrated that miR-126 down-regulates VCAM-1 in HUVECs [11].
Here we show that an increase in miR-126 is concomitant with an
increase in VCAM-1 and SDF-1 expression. We also found that miR-
126 antisense treatment strongly enhanced the expression of the miR-
126-speciﬁc targets VCAM and CXCL12/SDF1 as expected from the
mechanism of action classically described for miRNAs, indicating that,
at least in vitro, upregulation of miR126-speciﬁc targets is a
consequence of a decrease in miR-126 expression, as expected. The
results observed in CKD and Apo-E-KO aortas, i.e. upregulation of
VCAM-1 and SDF-1 when miR-126 was enhanced are therefore
probably the consequence of other unidentiﬁed mechanisms which
could counterbalance the inhibitory effects of miR-126 on these targets.
Several miRNAs, including miR-126, are secreted by endothelial cells in
blood microvesicles [34,35]. These vesicles integrate recipient cells
where they induce the expression of SDF-1, which in turn attenuates
atherosclerosis [13]. Undiscovered mechanisms, including regulation
by other miRNAs [36], could be responsible for this enhancement in
SDF-1 and VCAM-1 despite the increase in miR-126. A single miRNA is
able to ﬁne-tune hundreds of mRNA targets. On the other hand, we
cannot rule out the possibility thatmiR-126 increases its protein targets
expression, as was already proven for miR-328 [37].Sevelamer has been demonstrated to prevent the progression of
vascular calciﬁcation in CKD and to normalize the endothelial
dysfunction induced by uremic toxins [38]. Our results show that this
drug also attenuates the alteration of miRNA expression in the present
CKD and atherosclerosis models. This was true for both miR-126 and
miR-223 which reﬂect respectively endothelial dysfunction [11] and
the inﬂammatory state [21]. A decrease of miR-143 is observed in
various smooth muscle cell pathologies where it induces an increase
of proliferation and a decrease of differentiation [14]. Sevelamer
increased the levels of this miRNA, and thus could potentially have a
beneﬁcial effect by decreasing proliferation and augmenting
differentiation of VSMCs. CKD is a systemic disease comprising
metabolic changes, acidosis, increased inﬂammatory responses, and
ﬁbrosis in vessels [38]. In contrast to the serum calcium level, the
serum phosphorus level remained unchanged in the various groups at
the early time-points (T2 and T4), when miRNA alterations were
already demonstrated, suggesting that increased phosphorus is not
the triggering factor that drives miRNA changes in CKD. The effect of
sevelamer might therefore be both dependent and independent of
serum phosphorus levels, since some alterations of miRNA expression
were found in SHAM mice where sevelamer did not alter serum
phosphorus. In that case sevelamer may act via its well-known anti-
oxidant and anti-inﬂammatory effects [38].
In support of miR-126, miR-143, miR-145 and miR-223 as putative
noninvasive biomarkers in our models, we show that they were all
detected in normal and pathological murine serum. Furthermore,
most of these miRNAs are regulated during the crucial stages leading
to CKD and atherosclerosis. At the earliest stage of uremia, miR-126,
miR-143 and miR-223 expression was signiﬁcantly decreased in sera
from Apo-E KO mice versus their WT counterparts, indicating that
thesemiRNAs are potential early biomarkers of atherosclerotic damage.
At the later stage of uremia, Apo-E KO mutation induces a decrease of
miR-126, miR-143 and miR-223. Also, CKD at this later stage of uremia
triggers a decrease of miR-126 and miR-143 expression. Interestingly,
miR-223 at T10 was decreased in serum from CKD mice compared to
SHAM mice, while miR-223 expression was increased in aortas. A
similar phenomenonwas observed by Kin et al. [39] who demonstrated
that miR-223 was increased in the wall tissue samples of patients
undergoing atherosclerotic abdominal aortic aneurysm repair and
aortic valve replacement surgery, but decreased in their serum. Other
very recent studies have shown that miR-145 and miR-155 are
decreased in the serum of patients with CKD [40], and that miR-21 is
deregulated in patients with acute kidney injury [41].
5. Conclusions
We show in our CKD and atherosclerotic models that four miRNAs
are deregulated during the course of aortic vascular calciﬁcation and
atherosclerosis and that sevelamer treatment reverses the alteration
of these miRNA expressions. Taken together, our results have led to
novel suggestions concerning miRNA regulation during the course of
CKD, and the treatment of its vascular disorders. These ﬁndings may
be useful in understanding the molecular mechanisms underlying the
vascular complications of CKD in patients suffering from cardiovascular
diseases, and, in the longer term, in designing innovative miRNA-
targeted treatments.
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